EP0177836A2
Expired / Lapsed
EP
⏱️ 0.0 years remaining
Process for the inactivation of virus in immunoglobulins
Assignee: Tanabe Pharma Corp
•
Filing: 1985-09-24
•
Granted: —
•
Expires: 2005-09-24
Abstract
Abstract 57 Virus-contaminated immunoglobulin can be virus-inactivated by heating it in a substantially dry state at a temperature of 30° to 100°C for a period of time sufficient for inactivating virus with maintaining original activity of the immunoglobulin. The addition of glycine, sodium chloride, sodium acetate, polyethylene glycol, albumin or mannitol enhances the effect and gives good solubility and good state to the solution of the virus-inactivated immunoglobulin.
Inventors
- 👤 Yahiro Uemura
- 👤 Katuhiro Uriyu
- 👤 Tsuyoshi Takahashi
- 👤 Takashi Goto
- 👤 Masahiro Funayama
- 👤 Masayuki Nishida
- 👤 Tadakazu Suyama
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-11-04 20:31
CPC Classifications
A; A61; A61K; A61K39/00; A61K39/395; A61K39/39591; A61L; A61L2/00; A61L2/02; A61L2/04; A61L2103/00; A61L2103/05; Y; Y10; Y10S; Y10S530/00; Y10S530/861; Y10S530/863
Claims Analysis
Total Claims: 15
Claim 1
Independent Claim
36 words
A process for virus-inactivating immunoglobulin comprising heating a composition containing the same in a substantially dry state at a temperature of 30° to 100°C for a period of time sufficient for inactivating a virus contained therein.
Claim 2
Dependent Claim
36 words
A process for virus-inactivating immunoglobulin comprising heating a composition containing the same in a substantially dry state at a temperature of 30° to 100°C for a period of time sufficient for inactivating a virus contained therein.
Claim 3
Dependent Claim
35 words
A process according to Claim 1, wherein the composition contains a stabilizer selected from the group consisting of glycine, alkalimetal chloride, alkalimetal acetate, polyethylene glycol, albumin and mannitol in an amount sufficient for stabilizing immunoglobulin.
Claim 4
Dependent Claim
21 words
A process according to Claim 1, wherein the composition is so purified for immunoglobulin as to be administered to a patient.
Claim 5
Dependent Claim
16 words
A process according to.Claim 1, wherein the composition has been lyophilized to the substantially dry state.
Claim 6
Dependent Claim
23 words
A process according to Claim 1, wherein the substantially dry state is in a moisture content of 3% or less of the composition.
Claim 7
Dependent Claim
16 words
A process according to Claim 1, wherein the immunoglobulin is of human, horse or mouse origin.
Claim 8
Dependent Claim
20 words
A process according to Claim 6, wherein the immunoglobulin of human or mouse is a polyclonal or a monoclonal antibody.
Claim 9
Dependent Claim
14 words
A process according to Claim 1, wherein the immunoglobulin is IgG, IgA or IgM.
Claim 10
Dependent Claim
15 words
A process according to Claim 2, wherein the stabilizer is alkalimetal chloride or alkalimetal acetate.
Claim 11
Dependent Claim
11 words
A process according to Claim 9, wherein the alkalimetal is sodium.
Claim 12
Dependent Claim
45 words
A process according to Claim 2, wherein the amount sufficient for stabilizing immunoglobulin corresponds to a concentration of the stabilizer of 0.01 to 4% (w/v) relative to 0.01 to 2% (w/v) solution of monoclonal immunoglobulin or 2 to 8% (w/v) solution of a polyclonal immunoglobulin.
Claim 13
Dependent Claim
26 words
A process according to Claim 2, wherein the stabilizer has been added to a solution of the composition to be made into a substantially dry state.
Claim 14
Dependent Claim
11 words
A virus-inactivated immunoglobulin prepared according to the process of Claim 2.
Claim 15
Dependent Claim
17 words
A virus-inactivated immunoglobulin prepared according to the process of any of claims 1 or 3 to 12.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.